Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y12 Inhibitor Therapy After Percutaneous Coronary Intervention in Chronic Kidney Disease: a Post Hoc Analysis of the TAILOR-PCI Study.
Mathew RO, Sidhu MS, Rihal CS, Lennon R, El-Hajjar M, Yager N, Lyubarova R, Abdul-Nour K, Weitz S, O'Cochlain DF, Murthy V, Levisay J, Marzo K, Graham J, Dzavik V, So D, Goodman S, Rosenberg YD, Pereira N, Farkouh ME.
Mathew RO, et al.
Cardiovasc Drugs Ther. 2022 Nov 29:10.1007/s10557-022-07392-2. doi: 10.1007/s10557-022-07392-2. Online ahead of print.
Cardiovasc Drugs Ther. 2022.
PMID: 36445624